EU Clinical Trial Information System (CTIS)

Brand Logo

Brand Logo Light

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

I searched for some studies on AstraZeneca Clinical Trials, and found these studies that may also be of interest to you.
Here is the link to my search results

Official Title

Roflumilast 500 µg

underlying medication: salmeterol 50 μg, twice daily, inhaled

Placebo

underlying medication: salmeterol 50 μg, twice daily, inhaled

The aim of the study is to compare the efficacy of roflumilast on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of salmeterol. The study duration will last up to 28 weeks. The study will provide further data on safety and tolerability of roflumilast.

Effect of roflumilast on lung function in chronic obstructive pulmonary disease (COPD) patients treated with salmeterol: The EOS Study (BY217/M2-127)

NCT ID

Therapeutic Area

500 µg, once daily, oral administration in the morning

Altana Pharma/Nycomed Investigational Site

Effect of roflumilast in COPD patients treated with salmeterol. A 24-week, double-blind study with 500 μg roflumilast once daily versus placebo. The EOS Study

Mean change from baseline during the treatment period in pre-bronchodilator FEV1 [L]

Age Continuous

Gender, Male/Female

ITT (Intention to Treat) analysis. Number of participants analyzed = number of participants with data available.

Pre-bronchodilator Forced expiratory volume in first second (FEV1)

Mean change from baseline during the treatment period in post-bronchodilator FEV1 [L]

ITT analysis. Number of participants analyzed = number of participants with data available.

Post-bronchodilator FEV1

Mean rate of COPD exacerbations requiring rescue medication of 3 or more puffs/day on at least 2 consecutive days (=mild COPD exacerbations), or requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management [ATS / ERS 2005].

COPD Exacerbation Rate (mild, moderate or severe)

The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from –3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from –9 to +9.

Transition dyspnea index (TDI) focal score

Mean change from baseline during the treatment period in SOBQ. This is a 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. The questions were administered at visits V0, V2, V3, V4, V5, V6 and Vend to assess the perceived shortness of breath of the patient. For each activity listed in the questionnaire the patient should rate his/her breathlessness on a scale between zero and five, where zero is "not at all breathless" and five is "maximally breathless or too breathless to do the activity".

Arms	Assigned Interventions
Active Comparator: Roflumilast Roflumilast 500 µg underlying medication: salmeterol 50 μg, twice daily, inhaled	Drug: Roflumilast 500 µg, once daily, oral administration in the morning
Placebo Comparator: Placebo Placebo underlying medication: salmeterol 50 μg, twice daily, inhaled	Drug: Placebo once daily

Effect of roflumilast on lung function in chronic obstructive pulmonary disease (COPD) patients treated with salmeterol: The EOS Study (BY217/M2-127) - EOS

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator